Oricell Therapeutics announced $70M initial closing of Series C financing, to accelerate global development of solid tumor CAR-T therapies
On January 12, 2026, Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced the closing of a $70 million Series C1 financing.
The round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and a leading global healthcare fund, with participation from a sovereign wealth fund, NGS Super (NGS), E-Town Capital, Elikon Venture, and Talon Capital. Proceeds will accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving ways to commercialization.
Oricell is advancing a differentiated pipeline of CAR-T cell therapies for solid tumors, underpinned by three proprietary platforms developed over the past decade:
Ori®Ab: antibody discovery and engineering library
Ori®Armoring: enhancement of T-cell persistence and other crucial functions by TAs (Therapeutic Areas)
OnGo (Fast) CMC: rapid, scalable and effective manufacturing
Oricell has generated proof-of-concept (POC) clinical data across multiple pipeline CAR-T products. Its lead program, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma (HCC). Both a Phase I Investigator-Initiated Trial (IIT) and a Phase I IND study of Ori-C101 are completed. With far-leading-industry efficacy and safety profile, Ori-C101's clinical data have been featured at major academic conferences such as ASCO 2021 and ASCO 2025. Ori-C101 is entering the registrational pivotal trial and is well positioned to become the world's first approved CAR-T therapy for HCC.
Beyond Ori-C101, Oricell's integrated platforms are also yielding multiple next-generation CAR-T products with multi-targets and multi-mechanism designs. The innovative secreting CAR-T, OriC902, has shown groundbreaking efficacy and durability in ultra-late-line and difficult-to-treat solid tumor patients. Additionally, the company has initiated an IIT study to evaluate its proprietary dual-targeted in vivo CAR-T.
This USD financing will accelerate the internationalization and clinical development process of Oricell, solidify its technical strength in the cell therapy field, and enhance the value of its industrialization pipeline.